Sign up to receive OCREVUS updates

By registering at this site, you certify that you are a healthcare professional licensed in the United States or its territories and are indicating that you wish to receive information about OCREVUS, other Genentech products, and related disease education. Genentech's intent is to only provide information to healthcare professionals licensed in the United States or its territories who would likely be treating patients within the FDA-approved indications for this product.

Get the latest news, updates, and information about OCREVUS.

*Indicates required field

By completing and submitting this form, you agree to allow Genentech and its agents to collect the information provided and to be contacted by Genentech and its agents in the future regarding OCREVUS, other Genentech products, and related disease education. Genentech will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Genentech and its agents. Genentech will only use your information in accordance with its Privacy Policy.

Thank you

You are now signed up to receive information about OCREVUS (ocrelizumab) from Genentech.